Company LENZ Therapeutics, Inc.

Equities

LENZ

US52635N1037

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Share class

Shareholders

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
16.35 ^USD	-1.09%		+3.94%	0.00%

04-15	Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target	MT
04-15	William Blair Starts LENZ Therapeutics With Outperform Rating	MT

LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	25,568,779	24,078,774 ( 94.17 %)	34,321 ( 0.1342 %)	94.17 %

Name	Equities	%	Valuation
Versant Venture Management LLC 17.79 %	4,542,150	17.79 %	70 M $
RA Capital Management LP 16.37 %	4,178,823	16.37 %	65 M $
Alpha Wave Global LP 14.15 %	3,612,211	14.15 %	56 M $
Alpha Wave Global LP 14.15 %	3,612,211	14.15 %	56 M $
Point72 Asset Management LP 7.373 %	1,882,693	7.373 %	29 M $
EcoR1 Capital, LLC 4.777 %	1,219,774	4.777 %	19 M $
EcoR1 Capital, LLC 4.777 %	1,219,774	4.777 %	19 M $
Samsara Biocapital LLC 4.733 %	1,208,473	4.733 %	19 M $
Sectoral Asset Management, Inc. 4.185 %	1,068,675	4.185 %	17 M $
72 Investment Holdings LLC 3.986 %	1,017,751	3.986 %	16 M $

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.35 USD

Average target price

36.75 USD

Spread / Average Target

+124.77%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
LENZ THERAPEUTICS, INC.	0.00%	417M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs